PALBI评分在肝癌患者中的临床应用现状

Clinical application status of PALBI score in patients with liver cancer

肝癌是世界上第六常见的恶性肿瘤,也是全球癌症死亡的第三大原因。对于肝癌患者,无论采取任何治疗方式,均应评估患者的肝功能及治疗后并发症。目前许多肝功能储备模型被广泛应用于肝病患者的肝功能评估,但均有不可消除的局限性,所以人们迫切需要新的肝功能评估模型。血小板-白蛋白-胆红素(platelet-albumin-bilirubin,PALBI)评分是近年来提出的评估肝功能的新方法。该评分使用简单、客观的参数,可以将患者肝功能分层分级,更准确地评估患者的预后和生存。目前已有研究支持PALBI评分与肝癌患者肝切除术后、射频消融疗法、经动脉化疗栓塞、放射治疗、肝移植和靶向治疗的预后相关。现就国内外在该领域的研究,对PALBI评分在肝癌患者肝功能评估中的研究进展作一概述。

Liver cancer is the sixth most common malignant tumor in the world,and its mortality rate ranks the third in the world.For patients with liver cancer,regardless of the treatment method,the patients′liver function and post-treatment complications should be evaluated.At present,many liver function reserve models are widely used in liver function assessment in patients with liver disease,but due to their irreducible limitations,new models for liver function assessment are urgently needed.Platelet-albumin-bilirubin(PALBI)score is a new method proposed in recent years to evaluate liver function.Using simple,objective parameters,the score can stratify patients′liver function and more accurately assess the prognosis and survival of patients.Studies have supported the use of the PALBI score to be associated with the prognosis of patients with liver cancer after hepatectomy,radiofrequency ablation,transarterial chemoembolization,radiotherapy,liver transplantation,and targeted therapy.This article reviewed the research progress of PALBI score in liver function assessment.